About Anterios
Anterios is a company based in New York (United States) founded in 2006 by Robert Nicolosi and Jonathan T Edelson was acquired by Allergan in January 2016. Anterios has raised $26.9 million across 7 funding rounds from investors including Allergan, Ascent Biomedical Ventures and DRW Trading Group. Anterios operates in a competitive market with competitors including GSK, Avidity Biosciences, Revance Therapeutics, Sutro Biopharma and Antheia, among others.
- Headquarter New York, United States
- Founders Robert Nicolosi, Jonathan T Edelson
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Anterios Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Anterios
Anterios has successfully raised a total of $26.9M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $8.5 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Anterios
Anterios has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Allergan, Ascent Biomedical Ventures and DRW Trading Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
A venture capital firm focused on early-stage MedTech investments.
|
Locked | Locked | Locked |
Investor details for Anterios
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anterios
Investment portfolio details for Anterios
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Anterios
Detailed financials for Anterios
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anterios Comparisons
Peer comparison for Anterios
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anterios
Anterios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Revance Therapeutics, Sutro Biopharma and Antheia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
Detailed competitors of Anterios
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anterios
Complete news archive for Anterios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anterios
Anterios was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Anterios is headquartered in New York, United States. It is registered at New York, New York, United States.
Jonathan T Edelson is the current CEO of Anterios. They have also founded this company.
Anterios is a funded company, having raised a total of $26.9M across 7 funding rounds to date.
Anterios was a clinical stage company developing novel delivery technologies and formulations for neurotoxins through skin. Anterios NDS proprietary platform delivery technology enables local, targeted delivery of neurotoxins through the skin without the need for injections. NDS also enables the formulation of macromolecules as ready-to-use liquid injectable products. Its lead drug ANT-1207 is a topical formulation of botulinum toxin type A for the potential treatment of hyperhidrosis (excessive sweating), acne, and crows feet lines. The company has completed a pair of Phase II studies in acne, crows feet lines and Hyperhidrosis, according to ClinicalTrials.gov. The company was acquired by Allergan in Jan 2016, before which it spun out its other assets, including an injectable botulinum, into a new firm called Eirion Therapeutics.
Anterios's top competitors include Revance Therapeutics, Sutro Biopharma and Synthego.
Anterios has 7 investors. Key investors include Allergan, Ascent Biomedical Ventures, DRW Trading Group, Praesideo Management, and Quantum Technology Partners.